Angiodroid develops and commercializes an automatic CO2 dosing control system for angiographic imaging. Its CO2 injector is patented in Europe and the US and pending in China, and is commercialized in more than 55 countries. The system is designed to enable safer angiograms with fewer side effects while delivering imaging quality equal to standard contrast agents. Angiodroid has established commercial partnerships with MedTech companies including NGC Medical–Medtronic, Siemens Healthcare and Philips. Led by founder and CEO Sebastiano Zannoli, the company reported 2022 turnover of over €3M. The company is also developing Angiopulse, an IABP console for passive counterpulsation therapy, as part of its product roadmap. Angiodroid is a medical technology company based in San Lazzaro di Savena (Bologna), Italy, led by Founder and CEO Sebastiano Zannoli. It has developed a patented and CE‑marked exclusive automatic injection system for carbon dioxide angiography. The company cites core expertise in interventional cardiology, interventional radiology and vascular surgery. Angiodroid plans to use new funding to increase sales efforts and to introduce new products in its sector of focus. The article reports the company raised €1.5m in funding from strategic backers. A prior related round in October 2013 raised €900K. Angiodroid srl is a medical technology company headquartered in San Lazzaro di Savena (Bologna) with core expertise in hemodynamics, vascular surgery and interventional radiology. The company has developed a patented, CE-marked automatic injection system for carbon dioxide angiography accompanied by a disposable catheter kit. Founded by Sebastiano Zannoli (CEO) and Samuele Zannoli (software development manager), Angiodroid has partnered with hospitals such as San Raffaele (Milan), technology manufacturers and sales distributors. In October 2013 it raised €900K from business angels including investors associated with Italian Angels for Growth and Zernike MetaVentures (via the Ingenium Emilia Romagna fund). The company intends to use the funds to develop and commercialize new solutions in 2014 and to strengthen its sales force across Europe, India, Canada, the Middle East, China, Brazil and Africa.

Total raised

$10M

Funding rounds

3

Latest round

Series A

Latest activity

Feb 2023